trending Market Intelligence /marketintelligence/en/news-insights/trending/ul4fhwmzq3mblnxnvtlgba2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Eli Lilly to pay AC Immune CHF80M upfront in Alzheimer's drug collaboration deal

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Eli Lilly to pay AC Immune CHF80M upfront in Alzheimer's drug collaboration deal

Eli Lilly and Co. agreed with AC Immune SA to research and develop a new type of treatment for Alzheimer's disease and other degenerative disorders of the nervous system.

SNL Image

Under the license and collaboration agreement, Switzerland's AC Immune will receive an up-front payment of CHF80 million from Eli Lilly. AC Immune will be eligible to receive CHF60 million in near-term milestone payments and up to about CHF1.7 billion if long-term development, regulatory and commercial targets are met. Eli Lilly will also purchase a $50 million note convertible to equity in AC Immune.

ACI-3024, AC Immune's lead molecule, will be the primary focus of this collaboration. The experimental treatment was developed with the Swiss drugmaker's proprietary Morphomer technology, which consists of several chemical series of small molecules called tau aggregation inhibitors, which help in reducing inflammation of nervous tissues — a key symptom of Alzheimer's disease.

AC Immune will carry out the phase 1 development of ACI-3024 and any other Morphomer-based tau aggregation inhibitors. Eli Lilly will carry out further clinical development in exchange for worldwide commercialization rights for the drugs for Alzheimer's disease. AC Immune will hold onto development rights for certain other therapeutic uses.

According to Indianapolis-based Eli Lilly, this transaction will not change its EPS for 2018. The license and collaboration agreement is subject to regulatory clearances and closing conditions.